Research

Agenda

THE JAK-STAT PATHWAY: 20 YEARS FROM DISCOVERY TO DRUGS

Building 45 - Natcher
NIH campus, Bethesda
September 22-24, 2011

Day 1: Thursday, September 22
Day 2: Friday, September 23
Day 3: Saturday, September 24

Day 1:       Thursday, September 22

7:30 a.m. Continental Breakfast / Check-in  
8:15 a.m. – 8:25 a.m. Welcome John O’Shea (NIH/NIAMS)
8:25 a.m. – 9:15 a.m. Plenary: Where JAK-STAT Came from and One Place I Hope It Goes James Darnell (Rockefeller University)
Session I Jaks, Signaling & Inhibitors (Chair, John O’Shea, NIH/NIAMS)
9:15 a.m. - 9:45 a.m. Probing Cytokine Receptor Signaling through Imaging and Protein Engineering K. Christopher Garcia (Stanford University)
9:45 a.m. – 10:15 a.m. Jak Inhibitors: That’s a Fact, Jak! John O’Shea (NIH/NIAMS)
10:15 a.m. – 10:45 a.m. Tofacitinib: An Investigational, Selective JAK Inhibitor for Treatment of Autoimmune Diseases Samuel Zwillich (Pfizer)
10:45 a.m. – 11:15 a.m. BREAK
11:15 a.m. – 11:45 a.m. JAK/STAT Signaling and MPN Phenotype Tony Green (Cambridge Institute for Medical Research)
11:45 a.m. – 12:15 p.m. Janus Kinase Inhibition: Myelofibrosis and Beyond Jordan Fridman (Incyte)
12:15 p.m. – 1:15 p.m. LUNCH
Session II Jaks, Signaling & Inhibitors II (Chair, James Darnell, Rockefeller University)
1:15 p.m. – 1:45 p.m. Therapeutic Opportunities Based on Oncogenic Jak Kinase Signaling in Lymphoma Louis Staudt (NIH/NCI)
1:45 p.m. – 2:15 p.m. Targeting JAK-STAT Signaling for Cancer Therapy Richard Jove (City of Hope)
2:15 p.m. – 2:45 p.m. Characterization of the Pseudokinase Domain of JAK2 Olli Silvennoinen (University of Tampere, Finland)
2:45 p.m. – 3:00 p.m. Preclinical Pharmacology and Early Clinical Evaluation of GLPG0634, a Selective Jak1 Inhibitor for the Treatment of Rheumatoid Arthritis Gerben van't Klooster (Galapagos NV)
3:00 p.m. – 3:15 p.m. Targeting STAT5 in CML: Mechanism-of-action of JAK2 Tyrosine Kinase Inhibitors Unmask a Direct BCR/ABL-STAT5 Axis Veronika Sexl (Veterinary University of of Vienna)
3:15 p.m. – 3:45 p.m. BREAK
Session III Biology of STATS (Chair, George Stark, Lerner Institute, Case Western)
3:45 p.m. – 4:15 p.m. To Modify or Not to Modify, That Is the STAT Question George Stark (Lerner Institute)
4:15 p.m. – 4:45 p.m. Jak-STAT Pathway and Obesity Andrew Larner (Virginia Commonwealth University)
4:45 p.m. – 5:15 p.m. Nongenomic Functions of STAT3 David Levy (NYU)
5:15 p.m. – 5:45 p.m. Dynamics of STAT3 Nuclear Trafficking Nancy Reich (Stony Brook University)
5:45 p.m. – 6:00 p.m. Protein Kinase CK2 Functions as a Positive Regulator of the JAK/STAT and NF-kappaB Pathways Tika Benveniste (University of Alabama)
6:00 p.m. – 6:15 p.m. Stat2 Directs the Stat1-independent Suppression of Legionella pneumophila Growth by IFN-Is Christian Schindler (Columbia University)

Day 2:       Friday, September 23

7:30 a.m. Continental Breakfast  
Session IV STATs, Cancer & STAT Inhibitors (Chair, David Levy, NYU)
8:15 a.m. – 8:45 a.m. The Transcription Factors Stat3 and Stat5 Are Potent Oncogenes and Promising Drug Targets Bernd Groner (Frankfurt)
8:45 a.m. – 9:15 a.m. Selective Inhibition of Stat3 Phosphorylation with Phosphopeptidomimetic Prodrugs Targeting the SH2 Domain Inhibits the Growth of Breast Tumor Xenografts in Mice John McMurray (MD Anderson Cancer Center)
9:15 a.m. – 9:45 a.m. Chemical Biology Approaches to Developing STAT Modulators David Frank (Harvard University)
9:45 a.m. – 10:15 a.m. A Division of Labor between STAT5A and STAT5B in CML Pathophysiology Isabelle Dusanter-Fourt (INSERM/ University Paris Descartes)
10:15 a.m. – 10:45 a.m. Nonconventional Approaches to Inhibition of Jak/STAT Signaling Nadya Tarasova (NCI)
10:45 a.m. – 11:15 a.m. BREAK
Session V STATs in Immunoregulation (Chair, Warren Leonard, NIH/NHLBI)
11:15 a.m. – 11:45 a.m. STAT4 Play Mark Kaplan (Indiana University)
11:45 a.m. – 12:15 p.m. New STATs on Memory CD4 T Cell Development Susan Kaech (Yale School of Medicine)
12:15 p.m. – 12:45 p.m. STAT Mediated Regulation of Th Cell Differentiation Riitta Lahesmaa (Turku Centre for Biotechnology, University of Turku, Finland)
12:45 p.m. – 1:15 p.m. STAT5 as a Modulator of Th Differentiation Warren Leonard (NIH/NHLBI)
1:15 p.m. - 2:15 p.m. LUNCH
Session VI Biology of STATs II (Chair, Lothar Hennighausen, NIH/NIDDK)
2:15 p.m. – 2:45 p.m. STAT5: From Basel to Bethesda and Beyond Lothar Hennighausen (NIH/NIDDK)
2:45 p.m. – 3:15 p.m. Role of Stats in Lineage Determination and Cell Death Regulation in Mammary Gland Christine Watson (Cambridge University)
3:15 p.m. – 3:45 p.m. Landscape of STAT-dependent Histone Epigenetic Modification in T Helper Cell Specification Yukka Kanno (NIH/NIAMS)
3:45 p.m. – 4:15 p.m. Epigenetic Regulation of Interferon-gamma Signaling Rod Bremner (Toronto Western Hospital)
4:15 p.m. – 4:45 p.m. What We Learned from Drosophila JAK & STAT Willis Li (UCSD)
4:45 p.m. – 5:15 p.m. Activated Stat is a Supercompetitor That Acts Independently of Myc, YAP, Wnt and Ribosome Biogenesis Erika Bach (NYU)
5:15 p.m. – 5:45 p.m. Localized JAK/STAT Signaling Maintains Tissue Shape during Morphogenesis Martin Zeidler (University of Sheffield)
5:45 p.m. – 6:00 p.m. Chromatin–associated Phosphorylation of Stat Transactivation Domains Is Catalyzed by Cdk8 of the Mediator Complex Pavel Kovarik (University of Vienna)
6:00 p.m. – 6:15 p.m. An Essential Role of Stat3 in PI3K-induced Oncogenic Transformation Jonathan Hart (The Scripps Research Institute)
6:15 p.m. POSTER SESSION / RECEPTION
ENTERTAINMENT: CIT Band

Day 3:       Saturday, September 24

7:30 a.m. Continental Breakfast  
Session VII STATs & Cancer (Chair, Richard Jove, City of Hope)
8:15 a.m. – 8:45 a.m. STAT3 in Cancer Inflammation and Immunity Hua Yu (City of Hope Medical Center)
8:45 a.m. – 9:15 a.m. STAT3, Auto-immunity and Cancer: When Does Enough Become Too Much? Valeria Poli (University of Turin)
9:15 a.m. – 9:45 a.m. The Tumorigenic Role of Stat3 in T-cell Anaplastic Large Cell Lymphoma Giorgio Inghirami (University of Turin)
9:45 a.m. – 10:15 a.m. Single Cell Signaling & STAT Physiology in Cancer and Inflammation by Isotopic Mass Cytometry Garry Nolan (Stanford University)
10:15 a.m. – 10:45 a.m. BREAK
10:45 a.m. – 11:15 a.m. STAT3 Targeting in Head & Neck Cancer Jennifer Grandis (University of Pittsburgh)
11:15 a.m. – 11:45 a.m. Stat5: Oncogene and Tumor Suppressor Richard Moriggl (Boltzmann Institute)
11:45 a.m. – 12:15 p.m. STAT3 as Inducer of Immune Evasion and Epigenetic Silencing of Tumor Suppressor Genes Mariusz Wasik (University of Pennsylvania)
12:15 p.m. – 12:45 p.m. The Good and Evil Faces of the Janus Kinases in Heath and Disease Thomas Waldmann (NIH/NCI)
12:45 p.m. – 1:00 p.m. Targeting the IL-6/Jak Pathway in Breast Cancer Jacqueline Bromberg (MSKCC)
1:00 p.m. – 2:00 p.m. LUNCH
Session VIII STATs & Infectious Disease (Chair, Manfred Boehm, NIH/NHLBI)
2:00 p.m. - 2:30 p.m. Inborn Errors of Human STAT1 Immunity Jean-Laurent Casanova (Rockefeller University)
2:30 p.m. – 3:00 p.m. Interferon and JAK-STAT Regulation by Cells and Viruses Curt Horvath (Northwestern University)
3:00 p.m. – 3:30 p.m. Hyper IgE Syndrome: From Wound Healing to Cell Reprogramming Manfred Boehm (NIH/NHLBI)
3:30 p.m. – 4:00 p.m. Modulating STAT Levels for Regulating Cytokine Effects During Viral Infections: Lessons from NK cells Christine Biron (Brown University)
4:00 p.m. – 4:30 p.m. STAT3 & Job’s Syndrome Steve Holland (NIH/NIAID)
ADJOURN